In April 2017, US FDA allowed marketing of first direct-to-consumer tests that provide risk information for 10 diseases or conditions, including:
A.
Parkinson's disease, a nervous system disorder impacting movement
B.
late-onset Alzheimer's disease, a progressive brain disorder that destroys memory and thinking skills
C.
celiac disease, a disorder resulting in the inability to digest gluten
D.
α1 antitrypsin deficiency, a disorder that raises the risk of lung and liver disease